<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sabage LE</submitter><funding>São Paulo Research Foundation</funding><funding>Research to Prevent Blindness, New York</funding><funding>Coordination for the Improvement of Higher Education Personnel</funding><funding>Stanford ChEM-H IMA</funding><funding>Stanford Center for Optic Disc Drusen</funding><funding>BrightFocus Foundation's Macular Degeneration Research Program</funding><funding>NIH HHS</funding><pagination>6929</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9737489</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(23)</volume><pubmed_abstract>Purpose: To determine the prevalence of SARS-CoV-2 in tear samples and to investigate whether it correlates with ocular findings and patients’ prognosis in Brazil. Methods: Tears were collected using Schirmer strips (SS) and conjunctival swabs (CS) from patients hospitalized with laboratory-confirmed SARS-CoV-2 infection. Samples were analyzed using qRT-PCR. Demographic and clinical data, ocular symptoms, and Schirmer tests (ST) were collected from patients. Charlson Comorbidity Index (CCI) was used to rate comorbidities, and patients were monitored until hospital discharge or death. Results: There were 61 hospitalized patients, 33 of which were diagnosed with COVID-19. Within the confirmed COVID-19 patients, SARS-CoV-2 was detected in 18.2% (n = 6) of CS and 12.1% (n = 4) of SS samples. Subjective and objective parameters for dry eye syndrome (e.g., ST COVID-19: 8.3 ± 6.4mm, non-COVID-19: 8.9 ± 6.6mm, p > 0.05) were comparable between COVID-19 (n = 33) and non-COVID-19 patients (n = 28). Among the 16 COVID-19 patients exhibiting ocular symptoms, only tearing was reported significantly more frequently when tear samples were positive for SARS-CoV-2 (p &lt; 0.05). Strikingly, patients whose tears tested positive for SARS-CoV-2 had significantly inferior CCI (pos.: 34.0 ± 31.8%, neg.: 67.6 ± 36.4%, p &lt; 0.05) and higher mortality rates (pos.: 50.0%, neg.: 7.4%, p &lt; 0.01). Conclusions: SARS-CoV-2 was detected with a prevalence of 18.2% on the ocular surface. Decreased CCI and increased mortality rate in the positive tear group suggests that viral detection may relate to prognosis and highlight the need of personal protective measures for healthcare professionals. Most of the patients, regardless of COVID-19 diagnosis, had low tear production and eye discomfort, possibly pointing to the need for artificial tear use during hospitalization.</pubmed_abstract><journal>Journal of clinical medicine</journal><pubmed_title>Conjunctival Swabs Reveal Higher Detection Rate Compared to Schirmer Strips for SARS-CoV-2 RNA Detection in Tears of Hospitalized COVID-19 Patients.</pubmed_title><pmcid>PMC9737489</pmcid><funding_grant_id>R01EY025225</funding_grant_id><funding_grant_id>R01EY031952</funding_grant_id><funding_grant_id>2020/07365-8</funding_grant_id><funding_grant_id>CAPES - Finance Code 001</funding_grant_id><funding_grant_id>R01EY024665</funding_grant_id><funding_grant_id>P30EY026877</funding_grant_id><funding_grant_id>2022/01956-0</funding_grant_id><funding_grant_id>R01EY030151</funding_grant_id><pubmed_authors>Sun YJ</pubmed_authors><pubmed_authors>Mahajan VB</pubmed_authors><pubmed_authors>Sabage J</pubmed_authors><pubmed_authors>Wolf J</pubmed_authors><pubmed_authors>Santos CF</pubmed_authors><pubmed_authors>Sabage LE</pubmed_authors><pubmed_authors>Mazzo A</pubmed_authors><pubmed_authors>Manzoni Lourencone LF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Conjunctival Swabs Reveal Higher Detection Rate Compared to Schirmer Strips for SARS-CoV-2 RNA Detection in Tears of Hospitalized COVID-19 Patients.</name><description>Purpose: To determine the prevalence of SARS-CoV-2 in tear samples and to investigate whether it correlates with ocular findings and patients’ prognosis in Brazil. Methods: Tears were collected using Schirmer strips (SS) and conjunctival swabs (CS) from patients hospitalized with laboratory-confirmed SARS-CoV-2 infection. Samples were analyzed using qRT-PCR. Demographic and clinical data, ocular symptoms, and Schirmer tests (ST) were collected from patients. Charlson Comorbidity Index (CCI) was used to rate comorbidities, and patients were monitored until hospital discharge or death. Results: There were 61 hospitalized patients, 33 of which were diagnosed with COVID-19. Within the confirmed COVID-19 patients, SARS-CoV-2 was detected in 18.2% (n = 6) of CS and 12.1% (n = 4) of SS samples. Subjective and objective parameters for dry eye syndrome (e.g., ST COVID-19: 8.3 ± 6.4mm, non-COVID-19: 8.9 ± 6.6mm, p > 0.05) were comparable between COVID-19 (n = 33) and non-COVID-19 patients (n = 28). Among the 16 COVID-19 patients exhibiting ocular symptoms, only tearing was reported significantly more frequently when tear samples were positive for SARS-CoV-2 (p &lt; 0.05). Strikingly, patients whose tears tested positive for SARS-CoV-2 had significantly inferior CCI (pos.: 34.0 ± 31.8%, neg.: 67.6 ± 36.4%, p &lt; 0.05) and higher mortality rates (pos.: 50.0%, neg.: 7.4%, p &lt; 0.01). Conclusions: SARS-CoV-2 was detected with a prevalence of 18.2% on the ocular surface. Decreased CCI and increased mortality rate in the positive tear group suggests that viral detection may relate to prognosis and highlight the need of personal protective measures for healthcare professionals. Most of the patients, regardless of COVID-19 diagnosis, had low tear production and eye discomfort, possibly pointing to the need for artificial tear use during hospitalization.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-19T06:38:23.229Z</modification><creation>2025-04-19T06:38:23.229Z</creation></dates><accession>S-EPMC9737489</accession><cross_references><pubmed>36498504</pubmed><doi>10.3390/jcm11236929</doi></cross_references></HashMap>